Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EBITDA: 2014-2025

Historic EBITDA for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$34.3 million.

  • Viridian Therapeutics, Inc.\DE's EBITDA rose 54.39% to -$34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 18.14%. This contributed to the annual value of -$270.3 million for FY2024, which is 14.05% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its EBITDA stood at -$34.3 million for Q3 2025, which was up 66.00% from -$100.9 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's EBITDA's 5-year high stood at -$14.0 million during Q3 2021, with a 5-year trough of -$100.9 million in Q2 2025.
  • Its 3-year average for EBITDA is -$66.3 million, with a median of -$66.5 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Viridian Therapeutics, Inc.\DE's EBITDA was 67.93% (2021), while the steepest drop was 179.02% (2021).
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's EBITDA stood at -$29.1 million in 2021, then slumped by 55.45% to -$45.2 million in 2022, then crashed by 46.92% to -$66.5 million in 2023, then declined by 21.38% to -$80.7 million in 2024, then spiked by 54.39% to -$34.3 million in 2025.
  • Its EBITDA was -$34.3 million in Q3 2025, compared to -$100.9 million in Q2 2025 and -$86.7 million in Q1 2025.